Cargando…

The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target

Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ziyi, Jia, Renxiang, Wang, Linlin, Yang, Qiwei, Hu, Xiaohai, Fu, Qiang, Zhang, Xinyu, Li, Wenya, Ren, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300834/
https://www.ncbi.nlm.nih.gov/pubmed/35875146
http://dx.doi.org/10.3389/fonc.2022.935593
_version_ 1784751292139175936
author Wang, Ziyi
Jia, Renxiang
Wang, Linlin
Yang, Qiwei
Hu, Xiaohai
Fu, Qiang
Zhang, Xinyu
Li, Wenya
Ren, Yi
author_facet Wang, Ziyi
Jia, Renxiang
Wang, Linlin
Yang, Qiwei
Hu, Xiaohai
Fu, Qiang
Zhang, Xinyu
Li, Wenya
Ren, Yi
author_sort Wang, Ziyi
collection PubMed
description Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also promotes the accumulation of genomic changes that eventually lead to tumorigenesis, tumor progression, and therapeutic resistance to DNA-damaging anti-tumor agents. Rad51 recombinase is a critical effector of homologous recombination, which is an essential DNA repair mechanism for double-strand breaks. Rad51 has been found to be upregulated in many malignant solid tumors, and is correlated with poor prognosis. In multiple tumor types, Rad51 is critical for tumor metabolism, metastasis and drug resistance. Herein, we initially introduced the structure, expression pattern of Rad51 and key Rad51 mediators involved in homologous recombination. Additionally, we primarily discussed the role of Rad51 in tumor metabolism, metastasis, resistance to chemotherapeutic agents and poly-ADP ribose polymerase inhibitors.
format Online
Article
Text
id pubmed-9300834
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93008342022-07-22 The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target Wang, Ziyi Jia, Renxiang Wang, Linlin Yang, Qiwei Hu, Xiaohai Fu, Qiang Zhang, Xinyu Li, Wenya Ren, Yi Front Oncol Oncology Defects in DNA repair pathways are emerging hallmarks of cancer. Accurate DNA repairs and replications are essential for genomic stability. Cancer cells require residual DNA repair capabilities to repair the damage from replication stress and genotoxic anti-tumor agents. Defective DNA repair also promotes the accumulation of genomic changes that eventually lead to tumorigenesis, tumor progression, and therapeutic resistance to DNA-damaging anti-tumor agents. Rad51 recombinase is a critical effector of homologous recombination, which is an essential DNA repair mechanism for double-strand breaks. Rad51 has been found to be upregulated in many malignant solid tumors, and is correlated with poor prognosis. In multiple tumor types, Rad51 is critical for tumor metabolism, metastasis and drug resistance. Herein, we initially introduced the structure, expression pattern of Rad51 and key Rad51 mediators involved in homologous recombination. Additionally, we primarily discussed the role of Rad51 in tumor metabolism, metastasis, resistance to chemotherapeutic agents and poly-ADP ribose polymerase inhibitors. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9300834/ /pubmed/35875146 http://dx.doi.org/10.3389/fonc.2022.935593 Text en Copyright © 2022 Wang, Jia, Wang, Yang, Hu, Fu, Zhang, Li and Ren https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Ziyi
Jia, Renxiang
Wang, Linlin
Yang, Qiwei
Hu, Xiaohai
Fu, Qiang
Zhang, Xinyu
Li, Wenya
Ren, Yi
The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title_full The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title_fullStr The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title_full_unstemmed The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title_short The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
title_sort emerging roles of rad51 in cancer and its potential as a therapeutic target
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300834/
https://www.ncbi.nlm.nih.gov/pubmed/35875146
http://dx.doi.org/10.3389/fonc.2022.935593
work_keys_str_mv AT wangziyi theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT jiarenxiang theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT wanglinlin theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT yangqiwei theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT huxiaohai theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT fuqiang theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT zhangxinyu theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT liwenya theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT renyi theemergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT wangziyi emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT jiarenxiang emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT wanglinlin emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT yangqiwei emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT huxiaohai emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT fuqiang emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT zhangxinyu emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT liwenya emergingrolesofrad51incanceranditspotentialasatherapeutictarget
AT renyi emergingrolesofrad51incanceranditspotentialasatherapeutictarget